ILK and lung carcinoma: The modulatory properties of this substance are provided by decreasing the expression of cellular integrins β1, β4, integrin-linked kinase (ILK), and focal adhesion kinase (FAK) pathways, as well as β-catenin in lung cancer cells [45].